PPARG and metabolic disease: PPARγ agonists, such as the long chain fatty acid (FA) docosahexaenoic acid (DHA), improve metabolic disease in both human and animal models and increase PPARγ mediated transcription of targets such as adiponectin [11, 13, 14].